1. Home
  2. IRMD vs JANX Comparison

IRMD vs JANX Comparison

Compare IRMD & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iRadimed Corporation

IRMD

iRadimed Corporation

HOLD

Current Price

$92.02

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$15.83

Market Cap

975.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IRMD
JANX
Founded
1992
2017
Country
United States
United States
Employees
166
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
975.7M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
IRMD
JANX
Price
$92.02
$15.83
Analyst Decision
Strong Buy
Buy
Analyst Count
1
13
Target Price
$116.00
$47.00
AVG Volume (30 Days)
109.3K
721.4K
Earning Date
05-01-2026
05-08-2026
Dividend Yield
0.95%
N/A
EPS Growth
16.67
N/A
EPS
0.86
N/A
Revenue
$83,814,000.00
$10,000,000.00
Revenue This Year
$12.38
N/A
Revenue Next Year
$11.31
N/A
P/E Ratio
$106.06
N/A
Revenue Growth
14.43
N/A
52 Week Low
$67.84
$12.12
52 Week High
$107.90
$35.34

Technical Indicators

Market Signals
Indicator
IRMD
JANX
Relative Strength Index (RSI) 42.18 57.23
Support Level $90.96 $13.13
Resistance Level $97.63 $16.68
Average True Range (ATR) 3.10 0.63
MACD -0.50 -0.01
Stochastic Oscillator 18.99 78.06

Price Performance

Historical Comparison
IRMD
JANX

About IRMD iRadimed Corporation

iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: